Mainstream

Stanford university secures nih grant to advance tiakis biotech´s elafin (tiprelestat) through a u.s. phase ii trial in pulmonary arterial hypertension

Stanford University Secures NIH Grant to Advance tiakis Biotech´s Elafin (Tiprelestat) Through a U.S. Phase II Trial in Pulmonary Arterial Hypertension

Stanford University Secures NIH Grant to Advance tiakis Biotech´s Elafin (Tiprelestat) Through a U.S. Phase II Trial in Pulmonary Arterial Hypertension

- Novel, disease-modifying treatment option for Pulmonary Arterial Hypertension (PAH), an orphan indication with a significant unmet medical need

Kiel, GERMANY, September 8, 2025 –

You might also be interested in reading Avoiding the Icebergs: Three Rules for Surviving DeFi Lending.

September 8, 2025
In Mainstream